Takeda Pharmaceutical Co Ltd
TAK15.025USD
-0.084-0.56%
Cierre 04/25, 16:00（ET）Cotizaciones retrasadas 15 min
23.82BCap. mercado
0.11P/E TTM
Más Datos de Takeda Pharmaceutical Co Ltd Compañía
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Información de la empresa
Código de la empresaTAK
Nombre de la empresaTakeda Pharmaceutical Co Ltd
Fecha de salida a bolsaMay 16, 1949
Fundada en1925
Director ejecutivoMr. Christophe Weber
Número de empleados49281
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 16
Dirección4F
CiudadCHUO-KU
Bolsa de valoresNYSE Consolidated
PaísJapan
Código postal103-8668
Teléfono81332782111
Sitio Webhttps://www.takeda.com/
Código de la empresaTAK
Fecha de salida a bolsaMay 16, 1949
Fundada en1925
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: JPYHora de actualización: dom., 6 de abr
Divisa: JPYHora de actualización: dom., 6 de abr
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
Por negocioJPY
Nombre
Ganancia
Proporción
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Por regiónJPY
Nombre
Ganancia
Proporción
United States
593.84B
51.90%
Europe And Canada (Country)
262.60B
22.95%
Japan
108.34B
9.47%
Asia
69.19B
6.05%
Latin America
58.66B
5.13%
Other
51.53B
4.50%
Por negocio
Por región
Por negocioJPY
Nombre
Ganancia
Proporción
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Accionista
Hora de actualización: mar., 8 de abr
Hora de actualización: mar., 8 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Estadísticas de accionistas
Accionista
Proporción
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Tipo
Accionista
Proporción
Investment Advisor
1.55%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.27%
Research Firm
0.14%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.64%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
574
73.02M
2.32%
-10.12M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
2022Q4
637
69.93M
2.25%
-40.01M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital Research Global Investors
13.16M
0.42%
+25.31K
+0.19%
Dec 31, 2024
Parametric Portfolio Associates LLC
5.14M
0.16%
+961.51K
+23.02%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.22M
0.13%
-419.02K
-9.04%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.33M
0.11%
+438.69K
+15.18%
Dec 31, 2024
First Trust Advisors L.P.
3.24M
0.1%
+62.72K
+1.97%
Dec 31, 2024
Renaissance Technologies LLC
3.08M
0.1%
-139.40K
-4.33%
Dec 31, 2024
Brandes Investment Partners, L.P.
3.04M
0.1%
-192.02K
-5.94%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
2.32M
0.07%
+131.24K
+6.01%
Dec 31, 2024
Van Eck Associates Corporation
2.21M
0.07%
+35.19K
+1.62%
Dec 31, 2024
Aperio Group, LLC
2.20M
0.07%
+313.03K
+16.56%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
VanEck Pharmaceutical ETF
4.7%
SGI Enhanced Global Income ETF
3.05%
Roundhill GLP-1 & Weight Loss ETF
2.1%
ActivePassive International Equity ETF
0.6%
First Trust Value Line Dividend Index Fund
0.45%
Pacer Trendpilot International ETF
0.26%
Avantis International Equity ETF
0.07%
Avantis Responsible International Equity ETF
0.07%
DFA Dimensional International Core Equity 2 ETF
0%
Pacer Developed Markets International Cash Cws 100
0%
Ver más
VanEck Pharmaceutical ETF
Proporción4.7%
SGI Enhanced Global Income ETF
Proporción3.05%
Roundhill GLP-1 & Weight Loss ETF
Proporción2.1%
ActivePassive International Equity ETF
Proporción0.6%
First Trust Value Line Dividend Index Fund
Proporción0.45%
Pacer Trendpilot International ETF
Proporción0.26%
Avantis International Equity ETF
Proporción0.07%
Avantis Responsible International Equity ETF
Proporción0.07%
DFA Dimensional International Core Equity 2 ETF
Proporción0%
Pacer Developed Markets International Cash Cws 100
Proporción0%
Dividendos
Un total de
1.42T
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos